Tadamitsu Kishimoto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6157885/publications.pdf

Version: 2024-02-01

165 papers	42,823 citations	5248 83 h-index	7333 152 g-index
167 all docs	167 docs citations	167 times ranked	35127 citing authors

#	Article	IF	Citations
1	Epithelial miRâ€215 negatively modulates Th17â€dominant inflammation by inhibiting CXCL12 production in the small intestine. Genes To Cells, 2022, 27, 243-253.	0.5	0
2	The emerging role of Arid5a in cancer: A new target for tumors. Genes and Diseases, 2022, , .	1.5	0
3	IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19. Annual Review of Immunology, 2022, 40, 323-348.	9.5	50
4	Roles of RNA-binding proteins in immune diseases and cancer. Seminars in Cancer Biology, 2022, 86, 310-324.	4.3	14
5	Current status and prospects of IL-6â€“targeting therapy. Expert Review of Clinical Pharmacology, 2022, 15, 575-592.	1.3	10
6	Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	24
7	IL-6: from arthritis to CAR-T-cell therapy and COVID-19. International Immunology, 2021, 33, 515-519.	1.8	17
8	Reply to Cheng et al.: COVID-19 induces lower extent of cytokines, but damages vascular endothelium by IL-6 signaling. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2105040118.	3.3	0
9	Arid5a Promotes Immune Evasion by Augmenting Tryptophan Metabolism and Chemokine Expression. Cancer Immunology Research, 2021, 9, 862-876.	1.6	15
10	Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. Experimental and Molecular Medicine, 2021, 53, 1116-1123.	3.2	116
11	The novel long noncoding RNA AU021063, induced by IL-6/Arid5a signaling, exacerbates breast cancer invasion and metastasis by stabilizing Trib3 and activating the Mek/Erk pathway. Cancer Letters, 2021, 520, 295-306.	3.2	16
12	Recent Advances in the Role of Arid5a in Immune Diseases and Cancer. Frontiers in Immunology, 2021, 12, 827611.	2.2	6
13	IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22351-22356.	3.3	215
14	Historical overview of the interleukin-6 family cytokine. Journal of Experimental Medicine, 2020, 217, .	4.2	115
15	Noncanonical STAT1 phosphorylation expands its transcriptional activity into promoting LPS-induced IL-6 and IL-12p40 production. Science Signaling, 2020, 13, .	1.6	26
16	Arid5a, an RNA-Binding Protein in Immune Regulation: RNA Stability, Inflammation, and Autoimmunity. Trends in Immunology, 2020, 41, 255-268.	2.9	41
17	Translating IL-6 biology into effective treatments. Nature Reviews Rheumatology, 2020, 16, 335-345.	3.5	369
18	Feedback regulation of Arid5a and Ppar-Î³2 maintains adipose tissue homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15128-15133.	3.3	22

#	Article	IF	Citations
19	Targeting Interleukin-6 Signaling in Clinic. Immunity, 2019, 50, 1007-1023.	6.6	570
20	Discovery of IL-6 and Development of Anti-IL-6R Antibody. Keio Journal of Medicine, 2019, 68, 96-96.	0.5	7
21	Arid5a Regulation and the Roles of Arid5a in the Inflammatory Response and Disease. Frontiers in Immunology, 2019, 10, 2790.	2.2	29
22	Regulation of inflammatory responses by dynamic subcellular localization of RNA-binding protein Arid5a. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1214-E1220.	3.3	49
23	Arid5a stabilizes OX40 mRNA in murine CD4⁺ TÂcells by recognizing a stemâ€loop structure in its 3â€²UTR. European Journal of Immunology, 2018, 48, 593-604.	1.6	35
24	Interleukin (IL-6) Immunotherapy. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028456.	2.3	223
25	A Potential Therapeutic Target RNA-binding Protein, Arid5a for the Treatment of Inflammatory Disease Associated with Aberrant Cytokine Expression. Current Pharmaceutical Design, 2018, 24, 1766-1771.	0.9	14
26	Hairy Root Cultures of Eurycoma longifolia and Production of Anti-inflammatory 9-Methoxycanthin-6-one. Natural Product Communications, 2018, 13, 1934578X1801300.	0.2	2
27	The Two-Faced Cytokine IL-6 in Host Defense and Diseases. International Journal of Molecular Sciences, 2018, 19, 3528.	1.8	143
28	Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 11802-11807.	3.3	46
29	Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cellâ€“Mediated Antitumor Immunity By Suppressing PD-L1. Molecular Cancer Therapeutics, 2018, 17, 1941-1950.	1.9	10
30	The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Review of Clinical Immunology, 2017, 13, 535-551.	1.3	166
31	Arid5a-deficient mice are highly resistant to bleomycin-induced lung injury. International Immunology, 2017, 29, 79-85.	1.8	17
32	A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders. Trends in Molecular Medicine, 2017, 23, 348-361.	3.5	65
33	Therapeutic outlook for Castlemanâ€™s disease: prospects for the next decade. Expert Opinion on Orphan Drugs, 2017, 5, 633-640.	0.5	1
34	Expression of aryl hydrocarbon receptor, inflammatory cytokines, and incidence of rheumatoid arthritis in Vietnamese dioxin-exposed people. Journal of Immunotoxicology, 2017, 14, 196-203.	0.9	10
35	TLR4-induced NF-ÎºB and MAPK signaling regulate the IL-6 mRNA stabilizing protein Arid5a. Nucleic Acids Research, 2017, 45, 2687-2703.	6.5	129
36	Implications of IL-6 Targeting Therapy for Sepsis. Immunotherapy (Los Angeles, Calif), 2017, 03, .	0.1	1

#	Article	IF	Citations
37	Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy, 2016, 8, 959-970.	1.0	521
38	CD5: A New Partner for IL-6. Immunity, 2016, 44, 720-722.	6.6	9
39	Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10625-10630.	3.3	16
40	Arid5a exacerbates IFN-Î³â€“mediated septic shock by stabilizing T-bet mRNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11543-11548.	3.3	46
41	Regulation of IL-6 in Immunity and Diseases. Advances in Experimental Medicine and Biology, 2016, 941, 79-88.	0.8	135
42	Arid5a regulates naive CD4+ T cell fate through selective stabilization of Stat3 mRNA. Journal of Experimental Medicine, 2016, 213, 605-619.	4.2	76
43	Immunomodulatory drugs inhibit TLR4-induced type-1 interferon production independently of Cereblon via suppression of the TRIF/IRF3 pathway. International Immunology, 2016, 28, 307-315.	1.8	24
44	Interleukin 6. , 2016, , 686-692.		0
45	Suppressor of cytokine signallingâ€1 induces significant preclinical antitumor effect in malignant melanoma cells. Experimental Dermatology, 2015, 24, 864-871.	1.4	14
46	Aryl hydrocarbon receptor antagonism and its role in rheumatoid arthritis. Journal of Experimental Pharmacology, 2015, 7, 29.	1.5	39
47	Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2677-86.	3.3	174
48	Therapeutic uses of anti-interleukin-6 receptor antibody. International Immunology, 2015, 27, 21-29.	1.8	146
49	Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis. International Journal of Cardiology, 2015, 187, 319-321.	0.8	13
50	The aryl hydrocarbon receptor/microRNA-212/132 axis in T cells regulates IL-10 production to maintain intestinal homeostasis. International Immunology, 2015, 27, 405-415.	1.8	71
51	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. Modern Rheumatology, 2015, 25, 134-137.	0.9	26
52	IL-6: A New Era for the Treatment of Autoimmune Inflammatory Diseases. , 2015, , 131-147.		14
53	Aryl Hydrocarbon Receptor and Kynurenine: Recent Advances in Autoimmune Disease Research. Frontiers in Immunology, 2014, 5, 551.	2.2	115
54	A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Seminars in Immunology, 2014, 26, 88-96.	2.7	144

#	Article	IF	Citations
55	IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology, 2014, 6, a016295-a016295.	2.3	2,943
56	The Biology and Medical Implications of Interleukin-6. Cancer Immunology Research, 2014, 2, 288-294.	1.6	283
57	Interleukin 6. , 2014, , 1-8.		4
58	Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9409-9414.	3.3	179
59	The roles of aryl hydrocarbon receptor in immune responses. International Immunology, 2013, 25, 335-343.	1.8	157
60	Favorable Responses to Tocilizumab in Two Patients With Cancer-Related Cachexia. Journal of Pain and Symptom Management, 2013, 46, e9-e13.	0.6	36
61	Aryl hydrocarbon receptor and experimental autoimmune arthritis. Seminars in Immunopathology, 2013, 35, 637-644.	2.8	51
62	Aryl hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster promotes interleukin-17â€“producing T-helper cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11964-11969.	3.3	115
63	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. Modern Rheumatology, 2013, , 1.	0.9	12
64	Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan. Annals of the Rheumatic Diseases, 2013, 72, 627-628.	0.5	41
65	Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases. Inflammation and Regeneration, 2013, 33, 054-065.	1.5	13
66	A case of BehÃ§etâ€™s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Modern Rheumatology, 2012, 22, 298-302.	0.9	97
67	Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 387-397.	1.2	39
68	Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases. International Journal of Biological Sciences, 2012, 8, 1227-1236.	2.6	200
69	Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma. American Journal of Pathology, 2012, 180, 165-176.	1.9	115
70	Therapeutic Targeting of the Interleukin-6 Receptor. Annual Review of Pharmacology and Toxicology, 2012, 52, 199-219.	4.2	240
71	A case of BehÃ§etâ€™s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Modern Rheumatology, 2012, 22, 298-302.	0.9	64
72	Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. Modern Rheumatology, 2011, 21, 420-422.	0.9	15

#	Article	IF	Citations
73	Blockade of Interleukin-6 Signaling Suppresses Not Only Th17 but Also Interphotoreceptor Retinoid Binding Proteinâ€“Specific Th1 by Promoting Regulatory T Cells in Experimental Autoimmune Uveoretinitis. , 2011, 52, 3264.		70
74	Aryl hydrocarbon receptor deficiency in T cells suppresses the development of collagen-induced arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14222-14227.	3.3	111
75	Aryl hydrocarbon receptor negatively regulates LPS-induced IL-6 production through suppression of histamine production in macrophages. International Immunology, 2011, 23, 637-645.	1.8	81
76	Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology, 2011, 50, 1344-1346.	0.9	115
77	Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. Modern Rheumatology, 2011, 21, 420-422.	0.9	12
78	ILâ€6: Regulator of Treg/Th17 balance. European Journal of Immunology, 2010, 40, 1830-1835.	1.6	1,291
79	The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology, 2010, 49, 2408-2412.	0.9	177
80	Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19961-19966.	3.3	582
81	IL-6: from its discovery to clinical applications. International Immunology, 2010, 22, 347-352.	1.8	664
82	Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Modern Rheumatology, 2009, 19, 12-19.	0.9	312
83	Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. Journal of Experimental Medicine, 2009, 206, 2027-2035.	4.2	368
84	Successful treatment of reactive arthritis with a humanized antiâ€“interleukinâ€6 receptor antibody, tocilizumab. Arthritis and Rheumatism, 2009, 61, 1762-1764.	6.7	69
85	Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Modern Rheumatology, 2009, 19, 12-19.	0.9	228
86	Crucial role of the interleukinâ€6/interleukinâ€17 cytokine axis in the induction of arthritis by glucoseâ€6â€phosphate isomerase. Arthritis and Rheumatism, 2008, 58, 754-763.	6.7	123
87	Interleukinâ€6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis and Rheumatism, 2008, 58, 3710-3719.	6.7	211
88	Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet, The, 2008, 371, 998-1006.	6.3	734
89	Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9721-9726.	3.3	458
90	IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9041-9046.	3.3	308

#	Article	IF	Citations
91	Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Annals of the Rheumatic Diseases, 2007, 66, 1162-1167.	0.5	674
92	Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Research and Therapy, 2006, 8, S2.	1.6	396
93	Interleukin 6: from bench to bedside. Nature Clinical Practice Rheumatology, 2006, 2, 619-626.	3.2	536
94	Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis and Rheumatism, 2005, 52, 818-825.	6.7	336
95	INTERLEUKIN-6: From Basic Science to Medicineâ€"40 Years in Immunology. Annual Review of Immunology, 2005, 23, 1-21.	9.5	882
96	Humanized antiâ€"interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood, 2005, 106, 2627-2632.	0.6	670
97	Humanized Anti-Interleukin 6 Receptor Antibody Induced Long-term Remission in a Patient with Life-Threatening Refractory Autoimmune Hemolytic Anemia. International Journal of Hematology, 2004, 80, 246-249.	0.7	10
98	Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 2004, 50, 1761-1769.	6.7	751
99	A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohnâ€™s diseaseâ˜†. Gastroenterology, 2004, 126, 989-996.	0.6	600
100	Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis and Rheumatism, 2003, 48, 1521-1529.	6.7	359
101	ANTI-INTERLEUKIN 6 (IL-6) RECEPTOR ANTIBODY SUPPRESSES CASTLEMAN'S DISEASE LIKE SYMPTOMS EMERGED IN IL-6 TRANSGENIC MICE. Cytokine, 2002, 20, 304-311.	1.4	118
102	Receptor engagement by viral interleukin-6 encoded by Kaposi sarcomaâ€"associated herpesvirus. Blood, 2001, 98, 3042-3049.	0.6	68
103	Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood, 2000, 95, 56-61.	0.6	381
104	Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis and Rheumatism, 1999, 42, 1635-1643.	6.7	195
105	Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis and Rheumatism, 1998, 41, 2117-2121.	6.7	254
106	Postnatally Induced Inactivation of gp130 in Mice Results in Neurological, Cardiac, Hematopoietic, Immunological, Hepatic, and Pulmonary Defects. Journal of Experimental Medicine, 1998, 188, 1955-1965.	4.2	208
107	Wilms' Tumor Gene (WT1) Competes With Differentiation-Inducing Signal in Hematopoietic Progenitor Cells. Blood, 1998, 91, 2969-2976.	0.6	167
108	gp130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES. Annual Review of Immunology, 1997, 15, 797-819.	9.5	1,394

#	Article	IF	Citations
109	Cloning and Functional Analysis of New Members of STAT Induced STAT Inhibitor (SSI) Family: SSI-2 and SSI-3. Biochemical and Biophysical Research Communications, 1997, 237, 79-83.	1.0	164
110	Structure and function of a new STAT-induced STAT inhibitor. Nature, 1997, 387, 924-929.	13.7	1,224
111	Identification of alternative splicing form of Stat2. FEBS Letters, 1996, 381, 191-194.	1.3	12
112	The soluble form of the IL-6 receptor (sIL-6RÎ±) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6RÎ±-induced AIDS-KS cell growth. International Immunology, 1996, 8, 595-602.	1.8	52
113	Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. Journal of Bone and Mineral Research, 1996, 11, 88-95.	3.1	465
114	Identification of a Transcriptional Regulatory Factor for Human Aromatase Cytochrome P450 Gene Expression as Nuclear Factor Interleukinâ€6 (NFâ€IL6), a Member of the CCAAT/Enhancerâ€Binding Protein Family. FEBS Journal, 1995, 231, 292-299.	0.2	5
115	Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature, 1994, 368, 339-342.	13.7	1,680
116	Cytokine signal transduction. Cell, 1994, 76, 253-262.	13.5	1,318
117	Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. European Journal of Immunology, 1993, 23, 820-824.	1.6	195
118	Interleukin-6 in Biology and Medicine. Advances in Immunology, 1993, 54, 1-78.	1.1	1,191
119	Cytokine receptors and signal transduction. FASEB Journal, 1992, 6, 3387-3396.	0.2	225
120	IL-6 and NF-IL6 in Acute-Phase Response and Viral Infection. Immunological Reviews, 1992, 127, 25-50.	2.8	496
121	Site-specific mutagenesis of human interleukin-6 and its biological activity. FEBS Letters, 1991, 281, 167-169.	1.3	14
122	Augmentation of haptoglobin production in Hep3B cell line by a nuclear factor NF-IL6. FEBS Letters, 1991, 291, 58-62.	1.3	38
123	Chemical modification and 1H-NMR studies on the receptor-binding region of human interleukin 6. FEBS Journal, 1991, 196, 377-384.	0.2	24
124	V-ABL does not abolish IL-6 requirement by murine plasmacytoma cells. International Journal of Cancer, 1991, 48, 234-238.	2.3	3
125	The in vivo Antiâ€tumor Effect of Human Recombinant Interleukinâ€6. Japanese Journal of Cancer Research, 1990, 81, 1032-1038.	1.7	33
126	Direct evidence for the contribution of the unique I-ANOD to the development of insulitis in non-obese diabetic mice. Nature, 1990, 345, 722-724.	13.7	205

#	Article	IF	Citations
127	Studies on the structure and regulation of the human hepatic interleukin-6 receptor. FEBS Journal, 1990, 190, 79-83.	0.2	103
128	Interleukin 6 and its receptor in the immune response and hematopoiesis. International Journal of Cell Cloning, 1990, 8, 155-167.	1.6	25
129	Identification of the intracytoplasmic region essential for signal transduction through a B cell activation molecule, CD40. European Journal of Immunology, 1990, 20, 1747-1753.	1.6	89
130	Biological and clinical aspects of interleukin 6. Trends in Immunology, 1990, 11, 443-449.	7.5	1,038
131	Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB Journal, 1990, 4, 2860-2867.	0.2	1,204
132	Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell, 1990, 63, 1149-1157.	13.5	1,293
133	Structure-function analysis of human interleukin-6. FEBS Letters, 1990, 262, 323-326.	1.3	79
134	Mechanisms of differential regulation of interleukin-6 mRNA accumulation by tumor necrosis factor alpha and lymphotoxin during monocytic differentiation. FEBS Letters, 1990, 263, 349-354.	1.3	24
135	Current Concepts of B Cell Modulation. International Reviews of Immunology, 1989, 5, 97-109.	1.5	17
136	BSF-2/IL-6 does not augment Ig secretion but stimulates proliferation in myeloma cells. American Journal of Hematology, 1989, 31, 258-262.	2.0	34
137	Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell, 1989, 58, 573-581.	13.5	1,387
138	Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Letters, 1989, 250, 607-610.	1.3	377
139	Structure and Function of Fc _{Îµ} Receptor II (Fc _{Îµ} RII/CD23): A Point of Contact Between the Effector Phase of Allergy and B Cell Differentiation. Novartis Foundation Symposium, 1989, 147, 23-35.	1.2	10
140	Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/1L-6) in hepatocyte primary cultures. FEBS Journal, 1988, 173, 287-293.	0.2	183
141	Cell-free-synthesized interleukin-6 (BSF-2/IFN-beta2) exhibits hepatocyte-stimulating activity. FEBS Journal, 1988, 175, 181-186.	0.2	22
142	Effects of metabolite binding to ribulosebisphosphate carboxylase on the activity of the Calvin photosynthesis cycle. FEBS Journal, 1988, 177, 351-355.	0.2	102
143	A new interleukin with pleiotropic activities. BioEssays, 1988, 9, 11-15.	1.2	27
144	CDw40 and BLCa-specific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes. European Journal of Immunology, 1988, 18, 451-457.	1.6	28

#	Article	IF	Citations
145	Induction of rat acute-phase proteins by interleukin 6 in vivo. European Journal of Immunology, 1988, 18, 717-721.	1.6	394
146	Action of recombinant human interleukin 6, interleukin 1Î² and tumor necrosis factor Î± on the mRNA induction of acute-phase proteins. European Journal of Immunology, 1988, 18, 739-746.	1.6	255
147	Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies. European Journal of Immunology, 1988, 18, 951-956.	1.6	338
148	Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. European Journal of Immunology, 1988, 18, 1797-1802.	1.6	790
149	Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 1988, 332, 83-85.	13.7	1,631
150	Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Letters, 1988, 232, 347-350.	1.3	398
151	Recombinant human interleukin 6 (B-cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (M1). FEBS Letters, 1988, 234, 17-21.	1.3	158
152	Molecular structure of interleukin 6 receptor.. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 1988, 64, 209-211.	1.6	2
153	Interleukin 6 (BSF2/IL-6) is an autocrine growth factor for human multiple myelomas.. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 1988, 64, 68-71.	1.6	0
154	Prevention of autoimmune insulitis by expression of Iâ€“E molecules in NOD mice. Nature, 1987, 328, 432-434.	13.7	305
155	B cell stimulatory factor 2(BSF2/IL-6) and rheumatoid arthritis.. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 1987, 63, 281-283.	1.6	1
156	Transfer of the Ea gene into NOD mice prevents the development of autoimmune insulitis.. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 1987, 63, 155-157.	1.6	0
157	Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-Î²2) regulates Î²-fibrinogen and albumin mRNA levels in Fao-9 cells. FEBS Letters, 1987, 221, 18-22.	1.3	296
158	B-cell stimulatory factors (BSFs): Molecular structure, biological function, and regulation of expression. Journal of Clinical Immunology, 1987, 7, 343-355.	2.0	99
159	Identification of intrathymic T progenitor cells by expression of Thy-1, IL 2 receptor and CD3. European Journal of Immunology, 1987, 17, 1567-1571.	1.6	26
160	Differentiation of B cell progenitorsin vitro: Generation of surface IgM+ B cells, including Ly-1 B cells, from Thy-1â^' asialoGM1+ cells in newborn liver. European Journal of Immunology, 1987, 17, 1769-1774.	1.6	40
161	Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature, 1986, 324, 73-76.	13.7	2,028
162	IgM Induction in Murine B Hybridomas with Iaâ€Restricted T Cell Clones: A Monoclonal Model for T and B Cell Interactions in Antibody Response. Microbiology and Immunology, 1985, 29, 993-1003.	0.7	0

#	Article	IF	Citations
163	Regulation of B lymphocyte differentiation.. Japanese Journal of Medicine, 1985, 24, 186-187.	0.1	0
164	Regulation of the IgE antibody response.. Japanese Journal of Medicine, 1982, 21, 57-59.	0.1	0
165	(1) REGULATION OF THE IgE ANTIBODY RESPONSE. The Journal of the Japanese Society of Internal Medicine, 1981, 70, 1490-1493.	0.0	0